Altro Health raised $7 million to put peptides in gyms. The FDA hasn't approved any of it.
An NFX-backed startup wants peptides, GLP-1s and hormone therapy to be as easy to buy as a gym membership, on the strength of a regulatory vote that was only ever a recommendation.
A $7 million bet that gyms can sell medicine
Altro Health just raised a $7 million seed round led by NFX, with Founder Collective (an early backer of Whoop) and Abby Miller Levy of Primetime Partners also writing checks. The news, confirmed by AthleTech News and Fitt Insider on October 6, is straightforward: let personal trainers, gyms and medspas sell their own clients peptides, GLP-1s and hormone therapy, with a licensed clinical team handling the prescribing in the background. More than 500 businesses are already on the platform, which founder Andrea Corleto calls a clinical version of Shopify for wellness.
Corleto, a Harvard MBA who previously ran growth at a company that reached a $1 billion valuation, told AthleTech that the bigger opportunity isn't selling another supplement brand. Direct-to-consumer brands are fighting over the same customers, so we went after something bigger, she said. Instead, Altro sells infrastructure: a co-branded storefront, lab testing and a supply chain running through licensed 503A and 503B compounding pharmacies, with plans starting at $319 a month and rising to $599 for a Pro tier with its own domain and mobile blood draws.
What's actually on the menu
The products Altro is piping into gyms and medspas aren't FDA-approved drugs in the usual sense. Many are compounded peptides: BPC-157 for tissue repair, TB-500 for wound healing, epitalon and semax pitched for sleep and cognition, alongside GLP-1s and testosterone or estrogen therapy.
These sit in a regulatory gray zone that compounding pharmacies, not drug manufacturers, have historically filled. A substance only becomes compoundable at scale once it is added to the FDA's 503A bulks list, and for most of these peptides, that has not happened yet.
“Direct-to-consumer brands are fighting over the same customers, so we went after something bigger.”
The regulatory story is thinner than the pitch suggests
NFX's own investment post cites a policy shift that allows popular peptides to return to legal compounding status, pointing to a February 2026 announcement from HHS Secretary Robert F. Kennedy Jr. That announcement was political, not regulatory. No Federal Register notice formalized it, and the actual decision sits with the FDA's Pharmacy Compounding Advisory Committee, which reviewed just seven peptides at a meeting on July 23 and 24.
Healio's coverage of that meeting tells a more complicated story than peptides are legal now. The committee voted, narrowly, to recommend six of the seven for the 503A list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide failed. But those votes are advisory. The FDA has not acted on them, and formal rulemaking is expected to stretch into 2027.
What the committee actually overruled
What makes the vote more striking is who it overruled. Owais Durrani, DO, a Houston emergency physician who covered the meeting, said FDA staff reviewers went through all seven compounds and recommended against every one of them, and that reviewers could not find a single human clinical study for TB-500. The committee voted yes anyway. His read: recommending a substance for compounding when your own reviewers found no human data is a hard position to defend on the science.
“Anyone selling these next week on the strength of today's headlines is trying to dupe patients.”
Who's actually covered if something goes wrong
Altro's answer to the obvious safety question is that its network runs through licensed 503A and 503B pharmacies rather than the research chemical suppliers that already sell these same peptides online. That is a real distinction. State pharmacy and medical boards, along with several state attorneys general, have spent the past year flagging medspa peptide services for absentee physician supervision and for labeling injectable semaglutide as a research chemical to dodge prescribing rules. A platform with a named clinical team and licensed compounders is a meaningfully different setup from a website selling vials with no doctor involved.
But licensed sourcing does not retroactively create clinical evidence. If a gym sells TB-500 for soft tissue recovery, the person buying it still cannot point to a human trial showing it works for that. Durrani's warning about the committee vote applies just as directly to Altro's catalog: anyone selling these next week on the strength of today's headlines is trying to dupe patients. Nothing in that vote, or in Altro's $7 million round, changes what has actually been studied in people. For a longer look at the evidence behind one of the most popular peptides on offer, we've covered BPC-157 in more depth.
Our take
Altro's real innovation is distribution, not medicine. It makes it easy for a gym or medspa to add a peptide menu without hiring its own compliance team, and investors are right to see real demand there. But the regulatory cover the pitch leans on is softer than the FDA legalized this. A nonbinding committee vote that overruled FDA's own scientists, for a substance with zero human trials, is not the same as approval. If your gym starts offering BPC-157 or TB-500 next month, the honest framing is that you are an early, unstudied user, not a patient benefiting from settled science.
Health Trend Wire holds no position in Altro Health and was not paid for this article. This is general information, not medical or financial advice.
Frequently asked questions
Are peptides like BPC-157 legal to buy?
Not clearly. An FDA advisory committee voted in July 2026 to recommend BPC-157 for the legal compounding list, but that vote is nonbinding and the FDA has not acted on it. Licensed pharmacies can compound it for a prescription in some states, but it is not an FDA-approved drug for any condition, and formal rulemaking is not expected until 2027.
What is Altro Health?
Altro Health is a startup that provides the clinical backend, licensed prescribing, lab testing and pharmacy sourcing, that lets personal trainers, gyms and medspas sell peptides, GLP-1s and hormone therapy under their own brand. It raised a $7 million seed round led by NFX in October 2026 and says over 500 businesses use its platform.
Can gyms legally sell GLP-1 drugs?
Gyms cannot prescribe or dispense GLP-1 drugs themselves. Platforms like Altro connect a gym's clients to a licensed, remote clinical team that handles the prescription and a compounding pharmacy that fills it, with the gym acting as the storefront. The legal responsibility for prescribing still sits with the licensed providers, not the gym.
Is TB-500 FDA approved?
No. TB-500 is not an FDA-approved drug. An FDA advisory committee voted in July 2026 to recommend it for a list of substances that licensed pharmacies can legally compound, but FDA staff reviewers said they could not identify a single human clinical study supporting its use, and the FDA has not finalized the recommendation.
What are compounded peptides?
Compounded peptides are drug-like substances mixed to order by a licensed 503A or 503B pharmacy, rather than manufactured and approved by the FDA as a finished drug. They sit in a regulatory gray zone: legal to compound only for substances on the FDA's approved bulks list, which most popular peptides are not yet on.
Are medspa peptide treatments safe?
Safety depends heavily on sourcing and supervision. State pharmacy and medical boards have flagged medspas for absentee physician oversight and for mislabeling injectable drugs as 'research chemicals' to dodge prescribing rules. Treatments from licensed compounding pharmacies with real clinical oversight carry fewer sourcing risks, but most of these peptides still lack human safety and efficacy data.